Contribution: Industrial Research Assistance Program – Contributions to Firms
PEARKO Therapeutics Inc.
$295,500.00
Development of Novel Apelin Analog Drugs for Treatment of Cardiovascular Diseases
FY 2021-22 · 2021-11-01
Summary
PEARKO Therapeutics has been developing ApelinPlus (apelin analog) which can be a treatment for cardiovascular diseases. Currently, we are conducting preclinical testing of ApelinPlus, establishing required procedures, and preparing for regulatory filings with Health Canada, the Food and Drug Administration (FDA), and the European Medicines Agency (EMA).
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Edmonton|Edmonton, Alberta, Canada
Recipient Type
For-profit organization
Business Number
824764641
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2021-11-01 | 2021-22 | $400,000.00 |
| 1 | 2021-11-01 | 2021-22 | $295,500.00 |
| 2 | 2021-11-01 | 2021-22 | $295,500.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 122 days.
Additional Information (French)
Cet accord a été modifié 1 fois La date de fin du présent accord a été changé de 122 jours.
Agreement End Date
2024-03-31
Agreement Number
980844
Agreement Start Date
2021-11-01
Agreement Title
Development of Novel Apelin Analog Drugs for Treatment of Cardiovascular Diseases
Agreement Title (French)
Développement de nouveaux médicaments analogues de l'apeline pour le traitement des maladies cardiovasculaires
Agreement Type
Contribution
Agreement Value
$295,500.00
Amendment Date
2022-12-19
Amendment Number
2
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
PEARKO Therapeutics has been developing ApelinPlus (apelin analog) which can be a treatment for cardiovascular diseases. Currently, we are conducting preclinical testing of ApelinPlus, establishing required procedures, and preparing for regulatory filings with Health Canada, the Food and Drug Administration (FDA), and the European Medicines Agency (EMA).
Description (French)
PEARKO Therapeutics a développé ApelinPlus (analogue de l'apeline) qui peut être un traitement pour les maladies cardiovasculaires. Actuellement, nous effectuons des tests précliniques sur ApelinPlus, établissons les procédures requises et préparons les dépôts réglementaires auprès de Santé Canada, de la Food and Drug Administration (FDA) et de l'Agence européenne des médicaments (EMA).
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Edmonton Riverbend
Federal Riding (French)
Edmonton Riverbend
Federal Riding Number
48018
NAICS Code
541710
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
824764641
Recipient City
Edmonton|Edmonton
Recipient Country
CA
Recipient Legal Name
PEARKO Therapeutics Inc.
Recipient Postal Code
T6R 3A5
Recipient Province or Territory
AB
Recipient Type
F
Reference Number
172-2021-2022-Q3-980844
